SMA Archives -

Market Access/ News/ News/ News/ Sales and Marketing

Roche puts pressure on SMA rivals with new FDA approval

Phil Taylor Biogen, Evrysdi, Novartis, PTC Therapeutics, regulatory approval, Roche, SMA, Spinraza, Zolgensma 0 Comment

Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger

Roche puts pressure on SMA rivals with new FDA approval

https://pharmaphorum.com/news/roche-puts-pressure-on-sma-rivals-with-new-fda-approval/

News/ News/ R&D

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Richard Staines Evrysdi, Rare diseases, Roche, SMA 0 Comment

Roche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

https://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/

Market Access/ News/ News

NICE says NHS should fund Novartis’ £1.79m SMA gene therapy

Richard Staines market access, NICE, Novartis, SMA 0 Comment

The NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has

NICE says NHS should fund Novartis’ £1.79m SMA gene therapy

https://pharmaphorum.com/news/nice-says-nhs-should-fund-novartis-1-79m-sma-gene-therapy/

News/ News/ R&D

Novartis’ bid to expand use of SMA gene therapy delayed after FDA trial request

Richard Staines gene therapy, Novartis, rare disease, Roche, SMA, Zolgensma 0 Comment

Analysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal

Novartis’ bid to expand use of SMA gene therapy delayed after FDA trial request

https://pharmaphorum.com/news/novartis-bid-to-expand-use-of-sma-gene-therapy-delayed-after-fda-trial-request/

Market Access/ News/ News

Roche takes on pricey rivals as FDA approves SMA drug

Richard Staines Biogen, market access, neurology, Novartis, pricing, Roche, SMA 0 Comment

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA)

Roche takes on pricey rivals as FDA approves SMA drug

https://pharmaphorum.com/news/roche-takes-on-pricey-rivals-as-fda-approves-sma-drug/

News/ News/ R&D

Biogen plans trial of Spinraza in patients not responding to SMA gene therapy

Richard Staines Biogen, gene therapy, Novartis, Rare diseases, SMA, Spinraza, Zolgensma 0 Comment

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded

Biogen plans trial of Spinraza in patients not responding to SMA gene therapy

https://pharmaphorum.com/news/biogen-trialling-spinraza-in-patients-not-responding-to-novartis-sma-gene-therapy/

Market Access/ News/ News

Pandemic hits sales at Novartis after strong launch for SMA gene therapy

Richard Staines COVID-19, gene therapy, Novartis, Rare diseases, SMA, Zolgensma 0 Comment

The COVID-19 pandemic has bit into sales at Novartis, the big Swiss pharma said in second quarter results,

Pandemic hits sales at Novartis after strong launch for SMA gene therapy

https://pharmaphorum.com/news/pandemic-hits-sales-at-novartis-after-strong-launch-for-gene-therapy/

Market Access/ News/ News

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

Richard Staines AveXis, gene therapy, market access, Novartis, SMA, ultra-rare diseases 0 Comment

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euros

https://pharmaphorum.com/news/novartis-eyes-smart-deal-for-sma-gene-therapy-in-uk/

Market Access/ News/ News

Novartis offers reimbursement options as EU backs costly SMA therapy

Richard Staines AveXis, Biogen, neurology, Novartis, Rare diseases, Roche, SMA, Zolgensma 0 Comment

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare

Novartis offers reimbursement options as EU backs costly SMA therapy

https://pharmaphorum.com/news/novartis-reimbursement-options-as-eu-approves-ultra-pricey-sma-drug/

Trending

SMA

Login